ODTX

Odyssey Therapeutics, Inc.

Nasdaq · CIK 0001882782
$16.90 +0.54% $760.4M
Insider Buying Cluster (7 insiders)High Impact Filing (7/10)
Vol
Market Cap$760.4M
Cap SizeSmall Cap
Insider Activity7B / 1S
Insider Net $$69.3M
SEC Reports14
Press Releases1
Exchange Nasdaq·CIK 0001882782·Prev Close $16.81

Recent Activity

May 13, 2026 SEC
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling
CLUSTER — Impact 7/10
May 12, 2026 SEC
Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market purchases totaling ~
CLUSTER — Impact 7/10
May 12, 2026 SEC
Insider cluster at Odyssey Therapeutics shows $20.2M in open-market purchases by directors Li Nan and Chu Shelley at $18
CLUSTER — Impact 7/10
May 12, 2026 short_interest
FTD: ODTX — 61,094 shares ($1.1M) failed to deliver
Settlement: 20260512, Price: $17.45, FTD Value: $1,066,090.3, ODYSSEY THERAPEUTICS INC COM
May 11, 2026 Insider
Opipari Anthony W. acquired 6,965 shares
See Remarks
May 11, 2026 Insider
Opipari Anthony W. acquired via exercise 541 shares
See Remarks
May 11, 2026 Insider
Opipari Anthony W. surrendered for taxes 4 shares
See Remarks @ $18.00 ($72.00)
May 8, 2026 Press
Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent private placement of 1.39
Impact 5/10

Price Targets

$32.00 +89.3% upside Strong Buy
Current $16.90 Low $26.00 Median $30.00 High $40.00 3 analysts
$26.00 $40.00

Analyst Ratings

Recent Analyst Actions
DateFirmActionRating
Jun 2, 2026 Cantor Fitzgerald INITIATE Overweight
Jun 2, 2026 TD Cowen INITIATE Buy
Jun 2, 2026 Wedbush INITIATE Outperform
Jun 2, 2026 JP Morgan INITIATE Overweight
Jun 2, 2026 Oppenheimer INITIATE Outperform

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-1.28 $-1.43 — $-1.13 2
Next Q $-0.83 $-0.90 — $-0.74 3
Current FY $-3.56 $-3.89 — $-3.23 2
Next FY $-3.83 $-4.70 — $-2.90 -7% YoY 3

Latest Reports

BULLISH CLUSTER 7/10
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market purchases totaling
May 13, 2026
BULLISH CLUSTER 7/10
Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market purchases totaling ~
May 12, 2026
NEUTRAL Press 5/10
Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent private placement of 1.39
May 8, 2026

Recent Insider Trades

DateInsiderTypeValue
May 11, 2026Opipari AnthonyC$0.00
May 11, 2026Opipari AnthonyM$0.00
May 11, 2026Opipari AnthonyF$72.00
May 11, 2026Opipari AnthonyC$0.00
May 11, 2026Opipari AnthonyC$0.00
∅

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

15 unique insiders with 50 transactions. Net insider value: $69.3M ($69.3M bought, $19.2K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 11, 2026Opipari Anthony W.See RemarksCONVERT6,965——
May 11, 2026Opipari Anthony W.See RemarksEXERCISE541——
May 11, 2026Opipari Anthony W.See RemarksTAX W/H4$18.00$72.00
May 11, 2026Opipari Anthony W.See RemarksCONVERT18,531——
May 11, 2026Opipari Anthony W.See RemarksCONVERT11,083——
May 11, 2026Opipari Anthony W.See RemarksCONVERT20,000——
May 11, 2026Opipari Anthony W.See RemarksCONVERT17,545——
May 11, 2026Chu ShelleyDirectorBUY11,111$18.00$200.0K
May 11, 2026Opipari Anthony W.See RemarksEXERCISE5,263——
May 11, 2026Glick Gary DSee RemarksCONVERT27,386——
May 11, 2026Glick Gary DSee RemarksCONVERT166,116——
May 11, 2026Glick Gary DSee RemarksCONVERT100,000——
May 11, 2026Li Nan (LN)DirectorCONVERT1,709,543——
May 11, 2026Li Nan (LN)DirectorBUY1,111,111$18.00$20.0M
May 11, 2026Li Nan (LN)DirectorCONVERT16,611,626——
May 11, 2026LEIDEN JEFFREY MDirectorCONVERT28,698——
May 11, 2026LEIDEN JEFFREY MDirectorEXERCISE2,963——
May 11, 2026LEIDEN JEFFREY MDirectorTAX W/H17$18.00$306.00
May 11, 2026LEIDEN JEFFREY MDirectorCONVERT79,166——
May 11, 2026LEIDEN JEFFREY MDirectorCONVERT100,000——
May 11, 2026LEIDEN JEFFREY MDirectorCONVERT96,002——
May 11, 2026LEIDEN JEFFREY MDirectorEXERCISE28,800——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerCONVERT474,048——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerEXERCISE191,541——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerSELL1,065$18.00$19.2K
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerEXERCISE1,861,211——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerBUY222,222$18.00$4.0M
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerCONVERT4,606,320——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerCONVERT1,299,842——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerCONVERT544,162——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerCONVERT600,142——
May 11, 2026SR ONE CAPITAL MANAGEMENT, LLC10%+ OwnerCONVERT6,644,650——
May 11, 2026TPG GP A, LLCJ423,111——
May 11, 2026TPG GP A, LLCCONVERT1,880,497——
May 11, 2026TPG GP A, LLCBUY1,388,889$18.00$25.0M
May 11, 2026TPG GP A, LLCJ423,111——
May 11, 2026TPG GP A, LLCCONVERT18,272,789——
May 8, 2026Haas JasonChief Financial OfficerBUY1,000$20.00$20.0K
May 8, 2026LEIDEN JEFFREY MDirectorBUY5,000$20.00$100.0K
May 8, 2026Dimension Capital II, L.P.DirectorCONVERT1,709,543——
May 8, 2026Dimension Capital II, L.P.DirectorBUY1,111,111$18.00$20.0M
May 8, 2026Dimension Capital II, L.P.DirectorCONVERT16,611,626——
May 7, 2026Tatsis OuraniaDirectorAWARD27,393——
May 7, 2026Walbert Timothy PDirectorAWARD27,393——
May 7, 2026SMITH IAN FDirectorAWARD27,393——
May 7, 2026Odegard ValerieDirectorAWARD27,393——
May 7, 2026Opipari Anthony W.See RemarksAWARD250,203——
May 7, 2026Glick Gary DSee RemarksAWARD884,450——
May 7, 2026Todd Collin MSee RemarksAWARD93,904——
May 7, 2026Dales NatalieSee RemarksAWARD79,773——
14 SEC filing reports analyzed. Sentiment: 3 bullish, 0 bearish, 3 mixed, 8 neutral. Avg impact: 3.9/10.
BULLISH CLUSTER 7/10
Odyssey Therapeutics insiders and a major investor (TPG GP A, LLC) have made significant open-market
May 13, 2026
BULLISH CLUSTER 7/10
Odyssey Therapeutics insiders, including Director Li Nan and Director Chu Shelley, made open-market
May 12, 2026
BULLISH CLUSTER 7/10
Insider cluster at Odyssey Therapeutics shows $20.2M in open-market purchases by directors Li Nan an
May 12, 2026
MIXED 424B4 6/10
Odyssey Therapeutics priced its IPO at $18.00 per share, raising $279.0 million (15.5M shares) plus
May 8, 2026
MIXED EFFECT 6/10
Odyssey Therapeutics' IPO registration (S-1) became effective on May 7, 2026, clearing the final reg
May 8, 2026
NEUTRAL 3 2/10
Timothy P. Walbert filed a Form 3 initial statement of beneficial ownership with the SEC upon becomi
May 8, 2026
NEUTRAL 3 2/10
Odyssey Therapeutics filed two Form 3 initial beneficial ownership statements for new insiders Ouran
May 8, 2026
NEUTRAL 3 2/10
Jolie M. Siegel filed a Form 3 initial beneficial ownership report upon becoming Executive Vice Pres
May 8, 2026
NEUTRAL 3 2/10
Jeffrey M. Leiden filed a Form 3 initial statement of beneficial ownership with the SEC, reporting d
May 8, 2026
NEUTRAL 3 2/10
Simeon George and SR One Capital Management, LLC filed a Form 3 initial statement of beneficial owne
May 8, 2026
NEUTRAL 3 2/10
Ian F. Smith filed a Form 3 initial statement of beneficial ownership with the SEC, reporting direct
May 8, 2026
NEUTRAL 3 1/10
Carolyn Ng filed an initial statement of beneficial ownership (Form 3) with the SEC, reporting no se
May 8, 2026
NEUTRAL 3 2/10
Paulina Hill filed a Form 3 initial statement of beneficial ownership with the SEC for Odyssey Thera
May 8, 2026
MIXED S-1/A 6/10
Odyssey Therapeutics, a clinical-stage biopharma focused on autoimmune/inflammatory diseases, filed
May 4, 2026
NEUTRAL 5/10
Odyssey Therapeutics priced its upsized IPO of 15.5M shares at $18.00/share, with a concurrent priva
May 8, 2026

Analyst Price Targets

$32.00 mean target +89.3% upside Strong Buy (1.20)
$26.00 Low $40.00 High
MetricValue
Current Price$16.90
Target Low$26.00
Target Mean$32.00
Target Median$30.00
Target High$40.00
# Analysts3
RecommendationStrong Buy (1.20)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-03-31
 $-1.28 $-1.43 $-1.13 — — — $0.0B — 2
Next Q
2026-06-30
 $-0.83 $-0.90 $-0.74 — — — $0.0B — 3
Current FY
2026-12-31
 $-3.56 $-3.89 $-3.23 — — — $0.0B — 2
Next FY
2027-12-31
 $-3.83 $-4.70 $-2.90 -7.4% — — $0.0B 0.0% 3

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-1.280
7d ago$0.000-1.280
30d ago$0.000-1.280
60d ago$0.000-1.280
90d ago$0.000-1.280
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 5 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Jun 2, 2026 Cantor Fitzgerald INITIATE — Overweight
Jun 2, 2026 TD Cowen INITIATE — Buy
Jun 2, 2026 Wedbush INITIATE — Outperform
Jun 2, 2026 JP Morgan INITIATE — Overweight
Jun 2, 2026 Oppenheimer INITIATE — Outperform
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 12, 2026
short_interest
FTD: ODTX — 61,094 shares ($1.1M) failed to deliver
Settlement: 20260512, Price: $17.45, FTD Value: $1,066,090.3, ODYSSEY THERAPEUTICS INC COM
May 11, 2026
short_interest
FTD: ODTX — 172,406 shares ($2.8M) failed to deliver
Settlement: 20260511, Price: $16.42, FTD Value: $2,830,906.52, ODYSSEY THERAPEUTICS INC COM
May 8, 2026
offering
Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering
Odyssey Therapeutics, Inc. announces pricing of its upsized IPO of 15,500,000 shares of its common stock at an IPO price of $18 per share.